Rodent models for the study of diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 291-327

  Mathews, Clayton E ^a   Leiter, Edward H ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970959775     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (466)

1. Von Mering J, Minkowski O. Nach pancreas extirpation. Arch Exp Pathol Pharmakol 1890;26:371-381.
2. Minkowski O. Weitere mittheilungen uber den diabetes mellitus nach exstirpatation des pankreas. Berliner Klin Wochenschr 29:90-94.
3. Banting FG, Best CH, Doffin GM, Gilchrist JA. Quatitative parallelism of effect of insulin in man, dog, and rabbit (Abstract). Am J Physiol 1923;63:391.
4. Banting FG, Best CH. The internal secretion of the pancreas. Lab Clin Invest 1922;7:251-266.
5. Mauvais-Jarvis F, Kahn CR. Understanding the pathogenesis and treatment of insulin resistance and type 2 diaetes mellitus: what can we learn from transgenic and knockout mice? Diabetes Metab 2000;26:433-448.
6. Accili D, Nakae J, Kim JJ, et al. Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. . Pediatr Endocrinol Metab 1999;12:475-485.
7. Hattori M, Yamato E, Hirokawa KJ, et al. Male backcross mice of NOD with Mus spretus Spain predominantly develop diabetes regardless of MHC homozygosity and heterozygosity. Diabetes 1992;41:93A.
8. Hattori M, Yamato E, Matsumoto E, et al. Occurrence of pretype I diabetes (pre-IDDM) and type II diabetes (NIDDM) in BC1 [(NOD ?'Mus spretus)F1 ? NOD] mice. In: Shafrir E, ed. Lessons from animal diabetes, VI. Boston: Birkhauser, 1996:83-95.
9. Mehta V, Palmer JP. The natural history of the IDDM disease process. In: Palmer JP, ed. Prediction, prevention and genetic counseling in IDDM. New York: John Wiley & Sons, 1996:3-16.
10. Serreze DV, Leiter EH. Insulin dependent diabetes mellitus (IDDM) in NOD mice and BB rats: origins in hematopoietic stem cell defects and implications for therapy. In: Shafrir E, ed. Lessons from animal diabetes, V. London: Smith-Gordon, 1995:59-73.
11. Wang J, Takeuchi T, Tanaka S, et al. Amutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. . Clin Invest 1999;103:27-37.
12. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Exp Anim 1980;29:1-8.
13. Makino S, Hayashi Y, Muraoka Y, et al. Establishment of the nonobese-diabetic (NOD) mouse. In: Sakamoto N, Min HK, Baba S, eds. Current topics in clinical and experimental aspects of diabetes mellitus. Amsterdam: Elsevier, 1985: 25-32.
14. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. In: Dixon FJ, ed. Advances in immunology. New York: Academic Press, 1992:285-322.
15. Makino S, Yamashita H, Kunimoto K, et al. Breeding of the NON mouse and its genetic characteristics. In: Sakamoto N, Hotta N, Uchida K, eds. Current concepts of a new animal model: the NON mouse. Tokyo: Elsevier Science Publishers, 1992:4-10.
16. Hattori M, Fukuda M, Ichikawa T, et al. A single recessive non-MHC diabetogenic gene determines the development of insulitis in the presence of an MHC-linked diabetogenic gene in NOD mice. . Autoimmun 1990;3:1-10.
17. Ino T, Kawamoto Y, Sato K, et al. Selection of mouse strains showing high and low incidences of alloxan-induced diabetes. Jikken Dobutsu 1991;40: 61-67.
18. Ueda H, Ikegami H, Yamato E, et al. The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity. Diabetologia 1995;39:503-508.
19. Leiter EH. NOD mice and related strains: origins, husbandry, and biology. In: Leiter EH, Atkinson MA, eds. NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases. Austin, TX: R.G. Landes, 1998:1-35.
20. Baxter AG, Adams MA, Mandel TE. Comparison of high-and low-diabetes incidence NOD mouse strains. Diabetes 1989;38:1296-1300.
21. Bowman MA, Leiter EH, Atkinson MA. Autoimmune diabetes in NOD mice: a genetic programme interruptible by environmental manipulation. Immunol Today 1994;15:115-120.
22. Leiter E. The NOD mouse: a model for insulin dependent diabetes mellitus. In: Coligan JE, Kruisbeek AM, Margulies DM, et al, eds. Current protocols in immunology. New York: John Wiley & Sons, 1997:15.9.1-15.9.23.
23. Harano Y, Nakano T, Kosugi K, et al. Evaluation of ketosis and a role of insulin-antagonistic hormones in NOD mouse. In: Tarui S, Tochino Y, Nonaka K, eds. Insulitis and type 1 diabetes: lessons from the NOD mouse. Tokyo: Academic Press, 1986:233-238.
24. Coleman DL. Acetone metabolism in mice: increased activity in mice heterozygous for obesity genes. Proc Natl Acad Sci U S A 1980;77:290-293.
25. Harada M, Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice with cyclophosphamide. Diabetologia 1984;27:604-606.
26. Karasik A, Hattori M. Use of animal models in the study of diabetes. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus, 13th ed. Philadelphia: Lea & Febiger, 1994:317-350.
27. Colucci F, Bergman M-L, Penha-Gonclaves C, et al. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci U S A 1997;94:8670-8674.
28. Encinas JA, Wicker LS, Peterson LB, et al. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nat Genet 1999;21:158-160.
29. Lyons PA, Armitage N, Argentina F, et al. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res 2000;10:446-453.
30. Chesnut K, She JX, Cheng I, et al. Characterizations of candidate genes for IDD susceptibility from the diabetes-prone NOD mouse strain. Mamm Genome 1993;4:549-554.
31. Podolin P, Wilusz M, Cubbon R, et al. Differential glycosylation of interleukin-2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine 2000;12:477-482.
32. Prochazka M, Serreze DV, Frankel WN, et al. NOR/Lt mice: MHC-matched diabetes-resistant control strain for NOD mice. Diabetes 1992;41:98-106.
33. Reifsnyder PC, Flynn JC, Gavin AL, et al. Genotypic and phenotypic characterization of 6 new recombinant congenic strains containing NOD/Shi and CBA/J genome. Mamm Genome 1998;10:161-167.
34. Serreze DV, Fleming SA, Chapman HD, et al. B-lymphocytes are critical antigen presenting cells for the initiation of T cell mediated autoimmune insulin dependent diabetes in NOD mice. . Immunol 1998;161:3912-3918.
35. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunological function in NOD/LtSz-scid mice. . Immunol 1995;154:180-191.
36. Shultz LD, Lang PA, Christianson SW, et al. NOD/LtSz-Rag1(null) mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. . Immunol 2000;164:2496-2507.
37. Soderstrom I, Bergman ML, Colucci F, et al. Establishment and characterization of RAG-2 deficient non-obese diabetic mice. Scand J Immunol 1996;43: 525-530.
38. Worthen SM, Leiter EH, Shultz LD. The NOD-scid mouse: a model system for T cell transfer of diabetes [abstract]. Diabetes 1990;39:68A.
39. Serreze DV, Chapman HD, Post CM, et al. T* to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome rather than the cause of diabetes resistance elicited by immunostimulation. . Immunol 2001;166:1352-1359.
40. Fox CJ, Danska JS. Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes 1998; 47:331-338.
41. McAleer M, Reifsnyder P, Palmer S, et al. Crosses of NOD mice with the related NON strain: a polygenic model for type I diabetes. Diabetes 1995; 44:1168-1195.
42. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5:601-604.
43. Leiter EH. Genetics and immunogenetics of NOD mice and related strains. In: Leiter EH, Atkinson MA, eds. NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases. Austin, TX: R.G. Landes, 1998:37-69.
44. Jarpe AJ, Winter WE, Peck AB. The changing profile of mononuclear cell populations infiltrating the islets of Langerhan during the progressive insulitis phase in prediabetic NOD mice. Allerg Immunol 1990;9:283-292.
45. Jarpe A, Hickman M, Anderson J, et al. A. Flow cytometric enumeration of mononuclear cell populations infiltrating the islets of Langerhan in prediabetic NOD mice: development of a model of autoimmune insulitis for type I diabetes. Reg Immunol 1991;3:305-317.
46. Miyazaki A, Hanafusa T, Yamada K, et al. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin Exp Immunol 1985;60:622-630.
47. Faveeuw C, Gagnerault MC, Lepault F. Isolation of leukocytes infiltrating the islets of Langerhans of diabetes-prone mice for flow cytometric analysis. . Immunol Methods 1995;187:163-169.
48. Rohane PW, Shimada A, Kim DT, et al. Islet infiltrating lymphocytes from prediabetic NOD mice rapidly transfer diabetes to NOD-scid/scid mice. Diabetes 1995;44:550-554.
49. Amrani A, Durant S, Throsby M, et al. Glucose homeostasis in the nonobese diabetic mouse at the prediabetic stage. Endocrinology 1998;139:1115-1124.
50. Wilson SS, Deluca D. NOD fetal thymus organ-culture-an in vitro model for the development of T-cells involved in IDDM. . Autoimmun 1997;10:461-472.
51. Gaskins HR, Prochazka M, Hamaguchi K, et al. Beta cell expression of endogenous xenotropic retrovirus distinguishes diabetes susceptible NOD/Lt from resistant NON/Lt mice. . Clin Invest 1992;90:2220-2227.
52. Debussche X, Lormeau B, Boitard C, et al. Course of pancreatic beta cell destruction in prediabetic NOD mice a histomorphometric evaluation. Diabete Metab 1994;20:282-290.
53. Lafferty KJ. Immunobiology of autoimmune diabetes. Res Immunol 1997;148: 313-319.
54. Jansen A, Homo-Delarche F, Hooijkaas H, et al. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and D-cell destruction in NOD mice. Diabetes 1994; 43:667-675.
55. Sarukhan A, Gombert J-M, Olivi M, et al. Anchored polymerase chain reaction based analysis of the V?'repertoire in the non-obese diabetic (NOD) mouse. Eur J Immunol 1994;24:1750.
56. Haskins K, Portas M, Bergman B, et al. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sci U S A 1989;86:8000-8004.
57. Verdaguer J, Schmidt D, Averill N, et al. Spontaneous autoimmune diabetes in monoclonal T-cell nonobese diabetic mice. . Exp Med 1997;186:1663-1676.
58. DiLorenzo TP, Graser RT, Chapman HD, et al. Major histocompatibility complex class I restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc Natl Acad Sci U S A 1998;95:2538-2543.
59. Santamaria P, Utsugi T, Park B-J, et al. Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor a chain CDR3 sequences. . Immunol 1995;154:2494-2503.
60. Rothe H, Jenkins N, Copeland N, et al. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest 1997;99:469-474.
61. Rothe H, Hibino T, Martin S, et al. Systemic production of interferon-gamma, inducing factor (IGIF) versus local IFN-gamma expression involved in the development of T* insulitis in NOD mice. . Autoimmun 1997;10:251-256.
62. Trembleau S, Penna G, Gregori S, et al. Deviation of pancreas-infiltrating cells to TH2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 1997;27:2330-2339.
63. Fox C, Danska J. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. . Immunol 1997;158: 2414-2424.
64. Faveeuw C, Gagnerault MC, Kraal G, et al. Homing of lymphocytes into islets of Langerhans in prediabetic non-obese diabetic mice is not restricted to autoreactive T cells. Int Immunol 1995;7:1905-1913.
65. Yang XD, Michie SA, Tisch R, et al. Cell adhesion molecules: a selective therapeutic target for alleviation of IDDM. . Autoimmun 1994;7:859-864.
66. Signore A, Pozzilli P, Gale EAM, et al. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia 1989;32:282-289.
67. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice: relative contributions of CD4+ and CD8+ T lymphocytes from diabetic versus prediabetic NOD.NON-Thy 1a donors. Diabetes 1993;42:44-55.
68. Miller BJ, Appel MC, O'Neil JJ, et al. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. . Immunol 1988;140:52-58.
69. Serreze DV, Chapman HD, Varnum DS, et al. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. . Immunol 1997;158:3978-3986.
70. Bendelac A, Boitard C, Bedossa P, et al. Adoptive T cell transfer of autoimmune nonobese diabetic mouse diabetes does not require recruitment of host B lymphocytes. . Immunol 1988;141:2625-2628.
71. Akashi T, Nagafuchi S, Anzai K, et al. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in nonobese diabetic mice. Int Immunol 1997;9:1159-1164.
72. Noorchashm H, Noorchashm N, Kern J, et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997;46:941-946.
73. Serreze DV, Chapman HD, Varnum DS, et al. B lymphocytes are essential for the initiation of T cell mediated autoimmune diabetes: analysis of a new "speed congenic"stock of NOD.Igmnull mice. . Exp Med 1996;184:2049-2053.
74. Atkinson MA. NOD mice as a model for therapeutic interventions in human insulin dependent diabetes mellitus. In: Leiter EH, Atkinson MA, eds. NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases. Austin, TX: R. G. Landes, 1998:145-172.
75. Serreze DV, Hamaguchi K, Leiter EH. Immunostimulation circumvents diabetes in NOD/Lt mice. . Autoimmun 1989;2:759-776.
76. Bach J-F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15:516-542.
77. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997;7:291-297.
78. Liblau RS, Singer SM, McDevitt HO. T* and Th2 CD4+ T cells in the pathogenesis of organ specific autoimmune diseases. Immunol Today 1995;16:34-38.
79. Denny P, Lord CJ, Hill NJ, Goy JV, et al. Mapping of the IDDM locus Idd3 to a 0.35cM interval containing the interleukin-2 gene. Diabetes 1997;46:695-700.
80. Rothe H, Hartmann B, Geerlings P, et al. Interleukin-12 gene-expression of macrophages is regulated by nitric-oxide. Biochem Biophys Res Commun 1996; 224:159-163.
81. Rothe H, Burkart V, Faust A, et al. Interleukin-12 gene expression mediates the accelerating effect of cyclophosphamide in autoimmune disease. Ann N Y Acad Sci 1996;795:397-399.
82. Hultgren B, Huang XJ, Dybdal N, et al. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996;45:812-817.
83. Serreze DV, Post CM, Chapman HD, et al. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000;49:2007-2011.
84. Kanagawa O, Xu G, Tevaarwerk A, et al. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. . Immunol 2000;164:3919-3923.
85. Wang B, Andre I, Gonzalez A, et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci U S A 1997;94:13844-13849.
86. Sadelain MWJ, Qin H-Y, Lauzon J, et al. Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990;39:583-589.
87. Serreze DV, Gaedeke JW, Leiter EH. Hematopoietic stem cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci U S A 1993;90:9625-9629.
88. Clare-Salzler M. The immunopathogenic roles of antigen presenting cells in the NOD mouse. In: Leiter EH, Atkinson MA, eds. NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases. Austin, TX: R. G. Landes; 1998:101-120.
89. Varadhachary AS, Perdow SN, Hu C, et al. Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci U S A 1997;94:5778-5783.
90. Zhang X, Brunner T, Carter L, et al. Unequal death in T helper (Th)1 and Th2 effectors: T*, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. . Exp Med 1997;185:1837-1849.
91. Serreze DV, Leiter EH. Genes and pathways underlying autoimmune diabetes in NOD mice. In: von Herrath M, ed. Molecular pathology of insulindependent diabetes mellitus. New York: Karger; 2001.
92. Baekkeskov S, Kanaani J, Jaume JC, et al. Does GAD have a unique role in triggering IDDM? . Autoimmun 2000;15:279-286.
93. Hawa MI, Fava D, Medici F, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 2000; 23:228-233.
94. Wegmann DR, Eisenbarth GS. It's insulin. . Autoimmun 2000;15:286-291.
95. Yoon JW, Sherwin RS, Kwon H, et al. Has GAD a central role in type 1 diabetes? . Autoimmun 2000;15:273-278.
96. Kaufman DL, Clare-Salzler M, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72.
97. Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy-oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev 1993;9:279-287.
98. Tisch R, Yang XD, Liblau RS, et al. Administering glutamic acid decarboxylase to NOD mice prevents diabetes. . Autoimmun 1994;7:845-850.
99. Yoon JW, Yoon CS, Lim Hw, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in D'cells. Science 1999;284:1183-1186.
100. Eizirik DL, Hoorens A. D-cell dysfunction and death. Adv Mol Cell Biol 1999; 29:47-73.
101. Mathews C, Leiter E. Constitutive differences in anti-oxidant defense status distinguish alloxan aesistant (ALR/Lt) and alloxan susceptible (ALS/Lt) mice. Free Radic Biol Med 1999;27:499-455.
102. Mathews C, Leiter E. Resistance of ALR/Lt islets to free radical mediated diabetogenic stress is inherited as a dominant trait. Diabetes 1999;48: 2189-2196.
103. Mathews CE, Graser R, Savinov A, et al. The NOD/Lt-related ALR/Lt strain: unusual resistance of beta cells to autoimmune killing uncovers a role for beta-cell expressed resistance determinants. Proc Natl Acad Sci U S A 2001;98:235-240.
104. Prochazka M, Leiter EH, Serreze DV, et al. Three recessive loci required for insulin-dependent diabetes in NOD mice. Science 1987;237:286-289.
105. Mathews CE, Graser R, Savinov A, et al. The NOD/Lt-related ALR/Lt strain: unusual resistance of beta cells to autoimmune killing uncovers a role for beta-cell expressed resistance determinants. Proc Natl Acad Sci U S A 2001;98: 235-240.
106. Hattori M, Buse JB, Jackson RA, et al. The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 1986;231: 733-735.
107. Markees TG, Serreze DV, Phillips NE, et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999; 48:967-974.
108. Serreze DV. The identity and ontogenic origins of autoreactive T lymphocytes in NOD mice. In: Leiter EH, Atkinson MA, eds. NOD mice and related strains: research applications in diabetes, aids, cancer, and other diseases. Austin, TX: R. G. Landes; 1998:71-99.
109. Shimada A, Charlton B, Rohane P, et al. Immune regulation in type 1 diabetes. . Autoimmun 1996;9:263-269.
110. Carrasco-Marins E, Shimizu J, et al. The class II MHC I-Ag7 molecules from nonobese diabetic mice are poor peptide binders. . Immunol 1996;156: 450-458.
111. Slattery RM, Kjer-Nielsen L, Allison J, et al. Prevention of diabetes in nonobese diabetic I-Ak transgenic mice. Nature 1990;345:724-726.
112. Acha-Orbea H, McDevitt HO. The first external domain of the nonobese diabetic mouse class II I-AD'chain is unique. Proc Natl Acad Sci U S A 1987;84: 2435-2439.
113. Miyazaki T, Uno M, Uehira M, et al. Direct evidence for the contribution of the unique I-Anod to the development of insulitis in non-obese diabetic mice. Nature 1990;345:722-724.
114. Lund T, O'Reilly L, Hutchings P, et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A D-chain or normal I-E -chain. Nature 1990;345:727-729.
115. Hanson MS, Cetkovic-Cvrlje M, et al. Quantitative thresholds of MHC class II I-E expressed on hematopoietically derived APC in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. . Immunol 1996;157:1279-1287.
116. Lie BA, Sollid LM, Ascher H, et al. Agene telomeric of the HLA class I region is involved in predisposition to both type 1 diabetes and coeliac disease. Tissue Antigens 1999;54:162-168.
117. Hattori M, Yamato E, Itoh N, et al. Homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice. . Immunol 1999;163:1721-1724.
118. Ikegami H, Makino S, Yamato Y, et al. Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. . Clin Invest 1995;96:1936-1942.
119. Melanitou E, Joly F, Lathrop M, et al. Evidence for the presence of insulindependent diabetes-associated alleles on the distal part of mouse chromosome 6. Genome Res 1998;8:608-620.
120. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995;13:179-200.
121. Friday RP, Trucco M, Pietropaolo M. Genetics of type 1 diabetes mellitus. Diabetes Nutr Metab 1999;12:3-26.
122. McAleer MA, Reifsnyder P, Palmer SM, et al. Crosses of NOD mice with the related NON strain: a polygenic model for type I diabetes. Diabetes 1995;44: 1186-1195.
123. Leiter EH. Lessons from the animal models: the NOD mouse. In: Palmer JP, ed. Diabetes prediction, prevention, and genetic counselling. London: John Wiley & Sons, 1996:201-226.
124. Yui MA, Muralidharan K, Moreno-Altamirano B, et al. Production of congenic mouse strains carrying NOD-derived diabetogenic genetic intervals: an approach for the genetic dissection of complex traits. Mamm Genome 1996; 7:331-334.
125. Yui MA, Muralidharan K, Moreno-Altamirano B, et al. Production of congenic mouse strains carrying NOD-derived diabetogenic genetic intervals: an approach for the genetic dissection of complex traits. Mamm Genome 1996; 7:331-334.
126. Serreze DV, Chapman HC, Gerling IC, et al. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. . Immunol 1997;158: 3978-3986.
127. Serreze DV, Bridgett MB, Chapman HD, et al. Subcongenic analysis of the Idd13 locus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for D2-microglobulin. . Immunol 1998; 160:1472-1478.
128. Fox CJ, Paterson AD, Mortin-Toth SM, et al. Two genetic loci regulate T celldependent islet inflammation and drive autoimmune diabetes pathogenesis. Am J Hum Genet 2000;67:67-81.
129. Hattori M, Fukuda M, Ichikawa T, et al. A single recessive non-MHC diabetogenic gene determines the development of insulitis in the presence of an MHC-linked diabetogenic gene in NOD mice. . Autoimmun 1990;3:1-10.
130. Graser RT, Mathews CE, Leiter EH, et al. MHC characterization of ALR and ALS mice: respective similarities to the NOD and NON strains. Immunogenetics 1999;49:722-726.
131. Mathews CE, Graser RT, Serreze DV, et al. Re-evaluation of the major histocompatibility complex genes of the NOD progenitor CTS/Shi strain. Diabetes 2000;49:131-134.
132. Vafiadis P, Bennett S, Todd J, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Gen 1997;15: 289-292.
133. French M, Allison J, Dempseyc M, et al. Transgenic expression of mouse proinsulin-II prevents diabetes in nonobese diabetic mice. Diabetes 1997;46: 34-39.
134. Wong FS, Karttunen J, Dumont C, et al. Identification of an MHC class Irestricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999;5:1026-1031.
135. Hill NJ, Lyons PA, Armitage N, et al. The NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans. Diabetes 2000;49:1744-1747.
136. Marron M, Raffel L, Serranor M, et al. Insulin-dependent diabetes-mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnicgroups. Hum Mol Gen 1997;6:1275-1282.
137. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. . Immunol 1993;150: 2534-2543.
138. Langmuir PB, Bridgett MM, Bothwell ALM, et al. Bone marrow abnormalities in the non-obese diabetic mouse. Int Immunol 1993;5:169-177.
139. Dahlen E, Hedlund G, Dawe K. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. . Immunol 2000;164:2444-2456.
140. Bahjat FR, Dharnidharka VR, Fukuzuka K, et al. Reduced susceptibility of nonobese diabetic mice to TNF-alpha and D-galactosamine-mediated hepatocellular apoptosis and lethality. . Immunol 2000;165:6559-6567.
141. Prins J-B, Todd J, Rodriques N, et al. Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. Science 1993;260:695-698.
142. Martin R, Silva A, Lew A. The IgH-1 sequence of the nonobese diabetic (NOD) mouse assigns it to the IgG2C isotype. Immunogenetics 1997;46: 167-168.
143. Piganelli JD, Martin T, Haskins K. Splenic macrophages from the NOD mouse are defective in the ability to present antigen. Diabetes 1998;47: 1212-1218.
144. Peterson JD, Herzenberg LA, Vasquez K, et al. Glutathione levels in antigenpresenting cells modulate T* versus Th2 response patterns. Proc Natl Acad Sci U S A 1998;95:3071-3076.
145. Lee M, Kim AY, Kang Y. Defects in the differentiation and function of bone marrow-derived dendritic cells in non-obese diabetic mice. . Korean Med Sci 2000;15:217-223. 141a.Overbergh L, Decallonne B, Valckx D, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000;120:139-146.
146. Decallonne B, Overbergh L, Casteels KM, et al. Streptococcal wall component OK432 restores sensitivity of non-obese diabetic (NOD) thymocytes to apoptotic signals. Diabetologia 2000;43:1302-1308.
147. Leijon K, Hammarström B, Holmberg D. Non-obese diabetic (NOD) mice display enhanced immune responses and prolonged survival of lymphoid cells. Int Immunol 1994;6:339-345.
148. Penha-Goncalves C, Leijon K, et al. Type 1 diabetes and the control of dexamethazone-induced apoptosis in mice maps to the same region on chromosome 6. Genomics 1995;28:398-404.
149. Colucci F, Cilio CM, Lejon K, et al. Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. . Autoimmun 1996;9:271-276.
150. Lamhamedi Cherradi SE, Luan JJ, et al. Resistance of T-cells to apoptosis in autoimmune diabetic (NOD) mice is increased early in life and is associated with dysregulated expression of Bcl-x. Diabetologia 1998;41:178-184.
151. Martins TC, Aguas AP. NOD mice are resistant to depletion of thymic cells caused by acute stress or infection. Autoimmunity 1999;29:273-280.
152. Radosevic K, Casteels KM, Mathieu C, et al. Splenic dendritic cells from the non-obese diabetic mouse induce a prolonged proliferation of syngeneic T cells: a role for an impaired apoptosis of NOD T cells? . Autoimmun 1999;13: 373-382.
153. Casteels KM, Gysemans CA, Waer M, et al. Sex difference in resistance to dexamethasone-induced apoptosis in NOD mice: treatment with 1,25(OH)2D3 restores defect. Diabetes 1998;47:1033-1037.
154. Rapoport M, Lazarus A, Jaramillo A, et al. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. . Exp Med 1993;177:1221-1226.
155. Dardenne MF, Lepault A, Bendelac A, et al. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur J Immunol 1989;19: 889-895.
156. Ghosh S, Palmer SM, Rodrigues NR, et al. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat Genet 1993;4:404-409.
157. Chesnut K, Shie J-X, Cheng I, et al. Characterization of candidate genes for IDD susceptibility from the diabetes-prone NOD mouse strain. Mamm Genome 1993;4:549-554.
158. Horak I, Lohler J, Ma A, et al. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995;148:35-44.
159. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. . Immunol 1988;140:3801-3807.
160. Serreze DV, Leiter EH, Christianson GJ, et al. MHC class I deficient NODB2mnull mice are diabetes and insulitis resistant. Diabetes 1994;43:505-509.
161. Podolin PL, Wilusz MB, Cubbon RM, et al. Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine 2000;12:477-482.
162. Bach JF, Chatenou L, Carnaud C, et al. Autoimmune diabetes-how many steps for one disease. Res Immunol 1997;148:332-338.
163. Bendelac A, Rivera MN, Park SH, et al. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-562.
164. Gombert J, Herbelin A, Tancrede E C, et al. Early defect of immunoregulatory T-cells in autoimmune diabetes. . R Acad Sci III 1996;319:125-129.
165. Baxter AG, Kinder SJ, Hammond KJL, et al. Association between alpha-beta-TCR+CD4-CD8-T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46:572-582.
166. Hammond KJL, Poulton LD, Palmisano PA, et al. aD(TCR)+ CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in non-obese diabetic (NOD/Lt) mice by the influence of interleukin (IL)-4 and/or IL-10. . Exp Med 1998;187:1285-1292.
167. Gombert JM, Tancredebohin E, Hameg A, et al. IL-7 reverses NK1(+) T celldefective IL-4 production in the non-obese diabetic mouse. Int Immunol 1996; 8:1751-1758.
168. Carnaud C, Gombert JM, Donnars O, et al. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex. . Immunol 2001;166:2404-2411.
169. Serizawa I, Koezuka Y, Amao H, et al. Functional natural killer T cells in experimental mouse stains, including NK1.1-strains. Exp Anim 2000;49: 171-180.
170. Arase H, Arase N, Saito T. Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. . Exp Med 1996; 183:2391-2396.
171. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice: relative contributions of CD4+ and CD8+ T lymphocytes from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993;42:44-55.
172. Yanagi K, Haneji N, Hayashi Y, et al. Analysis of T-cell receptor V-beta usage in the autoimmune sialadenitis of nonobese diabetic (NOD) mice. Clin Exp Immunol 1997;110:440-446.
173. Papaccio G, Sellitti S, Salvatore G, et al. The Harderian gland in autoimmune diabetes of the nonobese diabetic mouse. Microsc Res Tech 1996;34: 156-165.
174. Hu Y, Nakagawa Y, Purushotham KR, et al. Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol 1992;263: E607-E614.
175. Takahashi M, Ishimaru N, Yanagi K, et al. High incidence of autoimmune dacryoadenitis in male non-obese diabetic (NOD) mice depending on sex steriod. Clin Exp Immunol 1997;109:555-561.
176. Skarstein K, Wahren M, Zaura E, et al. Characterization of T-cell receptor repertoire and anti-ro/ssa autoantibodies in relation to sialadenitis of NOD mice. Autoimmunity 1996;22:9-16.
177. Kerr M, Lee A, Wang P, Purushotham K, et al. Detection of insulin and insulin-like growth factors I and II in saliva and potential synthesis in the salivary glands of mice. Biochem Pharmacol 1995;49:1521-1531.
178. Hunger RE, Muller S, Laissue JA, et al. Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55. . Clin Invest 1996;98:954-961.
179. Robinson CP, Yamamoto H, Peck AB, et al. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996;79:50-59.
180. Robinson CP, Brayer J, Yamachika S, et al. Transfer of human serum IgG to NOD.Ignull mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjoren's syndrome. Proc Natl Acad Sci U S A 1998;95:7538-7543.
181. Delemarr F, Simons P, Drexhage H. The BB rat as a model for autoimmunethyroiditis-relevance for the pathogenesis of human disease. Exp Clin Endocrinol Diabetes 1996;104:10-12.
182. Many MC, Maniratunga S, Varis I, et al. Two-step development of Hashimotolike thyroiditis in genetically autoimmune prone non-obese diabetic mice: effects of iodine-induced cell necrosis. . Endocrinol 1995;147:311-320.
183. Many MC, Maniratu S, Denef JF. The nonobese diabetic (NOD) mouse-an animal model for autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 1996; 104:17-20.
184. Krug J, Williams AJK, Beales PE, et al. Parathyroiditis in the non-obese diabetic mouse-a new finding. . Endocrinol 1991;131:193-196.
185. Many M-C, Drexhage HA, Denef J-F. High frequency of thymic ectopy in thyroids from autoimmune prone nonobese diabetic female mice. Lab Invest 1993;69:364-367.
186. Bernard NF, Ertug F, Margolese H. High incidence of throiditis and anti-thyroid autoantibodies in NOD mice. Diabetes 1991;41:40-46.
187. Damotte D, Colomb E, Charreir J, et al. Analysis of susceptibility of NOD mice to spontaneous and experimentally-induced thyroiditis. Eur J Immunol 1997;27:2854-2882.
188. Margolese H, Okeefe C, Chung F, et al. Expression of major histocompatibility complex class II antigen in NOD mouse thyroid. Autoimmunity 1994;17: 1-11.
189. Leiter EH. The NOD mouse meets the "Nerup Hypothesis." Is diabetogenesis the result of a collection of common alleles present in unfavorable combinations? In: Vardi P, Shafrir E, eds. Frontiers in diabetes research: lessons from animal diabetes, III. London: Smith-Gordon, 1990:54-58.
190. Prochazka M, Gaskins HR, Shultz LD, et al. The NOD-scid mouse: a model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A 1992;89:3290-3294.
191. Atkinson M, Gendreau P, Ellis T, et al. NOD mice as a model for inherited deafness. Diabetologia 1997;40:868.
192. Zheng QY, Johnson KR, Erway LC. Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Hear Res 1999;130:94-107.
193. Baxter AG, Mandel TE. Hemolytic anemia in non-obese diabetic mice. Eur J Immunol 1991;21:2051-2055.
194. Gerling IC, Freidman H, Greiner DL, et al. Multiple low dose streptozotocininduced diabetes in NOD-scid/scid mice in the absence of functional lymphocytes. Diabetes 1994;43:433-440.
195. Baxter AG, Horsfall AC, Healey D, et al. Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice. Immunology 1994;83:227-231.
196. Mahler M, Leiter EH, Birkenmeier EH, et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 1998;274:G544-G551.
197. Amor S, Baker D, Groome N, et al. Identification of major encephalitogenic epitope of proteolipid protein (residues 56-70) for the induction of experimental allergic encephalomyelitis in Biozzi AB/H and nonobese diabetic mice. . Immunol 1993;150:5666-5672.
198. Winer S, Astsaturov I, Cheung R, et al. Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis. . Immunol 2001;166:2831-2841.
199. Nakhooda AF, Like AA, Chappel CI, et al. The spontaneously diabetic Wistar rat metabolic and morphologic studies. Diabetes 1976;26:100-112.
200. Crisa L, Mordes J, Rossini A. Autoimmune diabetes in the BB rat. Diabetes Metab Rev 1992;8:4-37.
201. Rossini AA, Handler ES, Mordes JP, et al. Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice-caveat emptor. Clin Immunol Immunopathol 1995;74:2-9.
202. Mordes JP, Groen H, Bortell R, et al. Autoimmune diabetes mellitus in the BB rat. In: Sima AAF, Shafrir E, eds. Animal models of diabetes: a primer. Amsterdam: Harwood Academic Publishers, 2001:1-41.
203. Mordes JP, Bortell R, Doukas J, et al. The BB/Wor rat and the balance hypothesis of autoimmunity. Diabetes Metab Rev 1996;12:103-109.
204. Like AA, Weringer EJ. Autoimmune diabetes in the biobreeding/Worcester rat. In: Lefèbvre PJ, Pipeleers DG, eds. The pathology of the endocrine pancreas in diabetes. Berlin, Heidelberg: Springer-Verlag, 1988:269-284.
205. Mordes JP, Desemone J, Rossini AA. The BB rat. Diabetes Metab Rev 1987;3: 725-750.
206. Jacob HJ, Pettersson A, Wilson D, et al. Genetic dissection of autoimmune type 1 diabetes in the BB rat. Nat Genet 1992;2:56-60.
207. Hornum L, Jackerott M, Markholst H. The rat T-cell lymphopenia resistance gene (Lyp) maps between D4Mit6 and Npy on RNO4. Mamm Genome 1995;6: 371-372.
208. Markholst H, Eastman S, Wilson D, et al. Diabetes segregates as a single locus in crosses between inbred BB rats prone or resistant to diabetes. . Exp Med 1991;174:297-300.
209. Iwakoshi NN, Goldschneider I, Tausche F, et al. High frequency apoptosis of recent thymic emigrants in the liver of lymphopenic diabetes-prone Bio-Breeding rats. . Immunol 1998;160:5838-5850.
210. Bortell R, Kanaitsuka T, Stevens LA, et al. The RT6 (Art2) family of ADP-ribosyltransferases in rat and mouse. Mol Cell Biochem 1999;193:61-68.
211. Koch-Nolte F, Duffy T, Nissen M, et al. New monoclonal antibody detects a developmentally regulated mouse ecto ADP ribosyltransferase on T cells: subset distribution, inbred strain variation, and modulation by T cell activation. . Immunol 1999;163:6014-6022.
212. Colle E, Guttman RD, Fuks A, et al. Genetics of the spontaneous diabetic syndrome: interaction of MHC and non-MHC associated factors. Mol Biol Med 1986;3:13-23.
213. Ellerman KE, Like AA. A major histocompatibility complex class II restriction for BioBreeding Worcester diabetes-inducing T cells. . Exp Med 1995;182: 923-930.
214. Awata T, Guberski DL, Like AA. Genetics of the BB rat: association of autoimmune disorders (diabetes, insulitis, and thyroiditis) with lymphopenia and major histocompatibility complex class II. Endocrinology 1995;136: 5731-5735.
215. Colle E. Genetic susceptibility to the development of spontaneous insulindependent diabetes mellitus in the rat. Clin Immunol Immunopathol 1990;57: 1-9.
216. Holowachuk EW, Greer MK. Unaltered class II histocompatibility antigens and pathogenesis of IDDM in BB rats. Diabetes 1989;38:267-271.
217. Chao NJ, Timmerman L, McDevitt HO, et al. Molecular characterization of MHC class II antigens (beta 1 domain) in the BB diabetes-prone and -resistant rat. Immunogenetics 1989;29:231-234.
218. MacMurray AJ, Moralejo DH, Kwitek AE, et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res 2002;12:1029-1039
219. Hornum L, Romer J, Markholst H. The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes 2002; 51:1972-1979.
220. Like AA, Guberski DL, Butler L. Diabetic BioBreeding/Worcester (BB/Wor) rats need not be lymphopenic. . Immunol 1986;136:3254-3258.
221. Martin AM, Blankenhorn EP, Maxson MN, et al. Non-major histocompatibility complex-linked diabetes susceptibility loci on chromosomes 4 and 13 in a backcross of the DP-BB/Wor rat to the WF rat. Diabetes 1999;48:50-58.
222. Kloting I, Kovacs P. Genes of the immune system cosegregate with the age at onset of diabetes in the BB/OK rat. Biochem Biophys Res Commun 1998;242: 461-463.
223. Kloting I, Schmidt S, Kovacs P. Mapping of novel genes predisposing or protecting diabetes development in the BB/OK rat. Biochem Biophys Res Commun 1998;245:483-486.
224. Kloting I, Van Den Brande J, Kovacs P. Quantitative trait loci for blood glucose confirm diabetes predisposing and protective genes, IDDM4 and IDDM5, in the spontaneously diabetic BB/OK rat. Int J Mol Med 1998;2: 597-601.
225. Kloting I, Vogt L, Serikawa T. Locus on chromosome 18 cosegregates with diabetes in the BB/OK rat subline. Diabete Metab 1995;21:338-344.
226. Ellerman K, Wrobleski M, Rabinovitch A, et al. Natural killer cell depletion and diabetes mellitus in the BB/Wor rat (revisited). Diabetologia 1993;36: 596-601.
227. Greiner DL, Mordes JP, Handler ES, et al. Depletion of RT6.1+ T lymphocytes induces diabetes in resistant Biobreeding/Worcester (BB/W) rats. . Exp Med 1987;166:461-475.
228. Whalen BJ, Greiner DL, Mordes JP, et al. Adoptive transfer of autoimmune diabetes mellitus to athymic rats: synergy of CD4(+) and CD8(+) T cells and prevention by RT6(+) T cells. . Autoimmun 1994;7:819-831.
229. Saoudi A, Seddon B, Fowell D, et al. The thymus contains a high-frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipents. . Exp Med 1996;184:2393-2398.
230. Iwakoshi NN, Greiner DL, Rossini AA, et al. Diabetes prone BB rats are severely deficient in natural killer T cells. Autoimmunity 1999;31:1-14.
231. Tori M, Ito T, Kitagawa-Sakakida S, et al. Importance of donor-derived lymphocytes in the protection of pancreaticoduodenal or islet grafts from recurrent autoimmunity: a role for RT6+NKR-P1+ T cells. Transplantation 2000;70: 32-38.
232. Trucco M, Laporte R. Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. . Pediatr Endocrinol Metab 1995; 8:3-10.
233. Rossini AA, Williams RM, Mordes JP, et al. Spontaneous diabetes in the gnotobiotic BB/W rat. Diabetes 1979;28:1031-1032.
234. Guberski D, Thomas V, Shek W, et al. Induction of type 1 diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 1991;254: 1010-1013.
235. Brown DW, Welsh RM, Like AA. Infection of peripancreatic lymph nodes but not islets precedes Kilham rat virus-induced diabetes in BB/Wor rats. . Virol 1993;67:5873-5878.
236. Ellerman KE, Richards CA, Guberski DL, et al. Kilham rat virus triggers Tcell-dependent autoimmune diabetes in multiple strains of rats. Diabetes 1996;45:557-562.
237. Chung YH, Jun HS, Kang Y, et al. Role of macrophages and macrophagederived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes in diabetes-resistant Biobreeding rats. . Immunol 1997;159: 466-471.
238. Kolb-Bachofen V, Schaermeyer U, Hoppe T, et al. Diabetes manifestation in BB rats is preceded by pan-pancreatic presence of activated inflammatory macrophages. Pancreas 1992;7:578-584.
239. Zipris D, Greiner DL, Malkani S, et al. Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated non-diabetic BB rats. . Immunol 1996;156: 1315-1321.
240. Rabinovitch A, Suarezpinzon W, Elsheikh A, et al. Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of T* cytokines correlates with beta-cell destructive insulitis and IDDM. Diabetes 1996;45:749-754.
241. Jiang Z, Handler ES, Rossini AA, et al. Immunopathology of diabetes in the RT6-depleted diabetes resistant BB/Wor rat. Am J Pathol 1990;137:767-777.
242. Scott FW, Cloutier HE, Kleemann R, et al. Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats-dose, timing, early effect on islet area, and switch in infiltrate from T* to TH2 cells. Diabetes1997;46:589-598.
243. Sobel DO, Goyal D, Chung YH, et al. Low dose poly I-C prevents diabetes in the diabetes prone BB rat. . Autoimmun 1998;11:343-352.
244. Huang XJ, Hultgren B, Dybdal N, et al. Islet expression of interferon-alpha precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunity 1994;1:469-478.
245. Sobel DO, Ahvazi B, Jun HS, et al. Cyclophosphamide inhibits the development of diabetes in the diabetes-prone BB rat. Diabetologia 2000;43: 986-994.
246. Sternthal E, Like AA, Sarantis K, et al. Lymphocytic thyroiditis and diabetes in the BB/W rat. A new model of autoimmune endocrinopathy. Diabetes 1981;30:1058-1061.
247. Rajatanavin R, Appel MC, Reinhardt W, et al. Variable prevalence of lymphocytic thyroiditis among diabetes-prone sublines BB/Wor rats. Endocrinology 1991;128:153-157.
248. Awata T, Kanazawa Y. Genetic-markers for insulin-dependent diabetes-mellitus in Japanese. Diabet Res Clin Pract 1994;24:S83-S87.
249. McKeever U, Mordes JP, Greiner DL, et al. Adoptive transfer of autoimmune diabetes and thyroiditis to athymic rats. Proc Natl Acad Sci U S A 1990;87: 7618-7622.
250. Gottlieb PA, Handler ES, Appel MC, et al. Insulin treatment prevents diabetes mellitus but not thyroiditis in RT6-depleted diabetes resistant BB/Wor rats. Diabetologia 1991;34:296-300.
251. Kawano K, Kirashima T, Mori S, et al. New inbred strain of Long-Evans Tokushima lean rats with IDDM without lymphopenia. Diabetes 1991;40: 1375-1381.
252. Komeda K, Noda M, Kanazawa M, et al. Establishment of 2 substrains, diabetes-prone and nondiabetic, from Long-Evans Tokushima-Lean (LETL) rats. . Endocrinol 1998;45:737-744.
253. Yokoi N, Kanazawa M, Kitada K, et al. A non-MHC locus essential for autoimmune type 1 diabetes in the Komeda diabetes-prone rat. . Clin Invest 1997;100:2015-2021. 247a.Yokoi N, Komeda K, Wang HY, et al. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nat Genet 2002;31:391-394.
254. Yoshioka M, Kayo T, Ikeda T, et al. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997;46:887-894.
255. Kayo T, Koizumi A. Mapping of murine diabetogenic gene mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and beta cell development during the perinatal period. . Clin Invest 1998;101:2112-2118.
256. Coleman DL, Eicher EM. Fat (fat) and tubby (tub), two autosomal recessive mutations causing obesity syndromes in the mouse. . Hered 1990;81:424-427.
257. Naggert JK, Fricker LD, Varlamov O, et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995;10:135-142.
258. Fricker LD, Snyder SH. Enkephalin convertase: purification and characterization of a specific enkephalin-synthesizing carboxypeptidase localized to adrenal chromaffin granules. Proc Natl Acad Sci U S A 1982;79:3886-3890.
259. Fricker LD. Carboxypeptidase E. Annu Rev Physiol 1988;50:309-321.
260. Eipper BA, Mains RE. Peptide alpha-amidation. Annu Rev Physiol 1988;50: 333-344.
261. Varlamov O, Leiter E, Fricker L. Induced and spontaneous mutations at Ser202 of carboxypeptidase E: effect on enzyme expression, activity, and intracellular routing. . Biol Chem 1996;271:13981-13986.
262. Leiter EH, Herberg L. The polygenetics of diabesity in mice. Diabetes Rev 1997;5:131-148.
263. Kim JH, Nishina PM, Naggert JK. Genetic models for non insulin dependent diabetes mellitus in rodents. . Basic Clin Physiol Pharmacol 1998;9:325-345.
264. Robinson SW, Dinulescu DM, Cone RD. Genetic models of obesity and energy balance in the mouse. Annu Rev Genet 2000;34:687-745.
265. Mammes O, Betoulle D, Aubert R, et al. Association of the G-2548A polymorphism in the 5_ region of the LEP gene with overweight. Ann Hum Genet 2000;64:391-394.
266. Ohshiro Y, Ueda K, Nishi M, et al. A polymorphic marker in the leptin gene associated with Japanese morbid obesity. . Mol Med 2000;78:516-520.
267. Roth H, Korn T, Rosenkranz K, et al. Transmission disequilibrium and sequence variants at the leptin receptor gene in extremely obese German children and adolescents. Hum Genet 1998;103:540-546.
268. Ingalls KA, Dickie MM, Snell GD. Obese, a new mutation in the mouse genome. . Hered 1950;41:317-318.
269. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
270. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-549.
271. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
272. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-543.
273. Chehab F, Lim M, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996;12:318-320.
274. Friedman JM. Leptin, leptin receptors and the control of bodyweight. Nutr Rev 1998;56:S38-S46.
275. Kerouz NJ, Horsch D, Pons S, et al. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. . Clin Invest 1997;100:3164-3172.
276. Frigeri LG, Wolff GL, Robel G. Impairment of glucose tolerance in yellow (Avy/A) (BALB/c X VY) F-1 hybrid mice by hyperglycemic peptide(s) from human pituitary glands. Endocrinology 1983;113:2097-2105.
277. Genuth SM, Przybylski RJ, Rosenberg DM. Insulin resistance in genetically obese, hyperglycemic mice. Endocrinology 1971;88:1230-1280.
278. Leiter E, Herberg L. The polygenetics of diabesity in mice. Diabetes Rev 1997; 5:131-148.
279. Herberg L, Coleman D. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 1977;26:59-99.
280. Coleman DL, Hummel KP. Hyperinsulinemia in preweaning diabetes (db) mice. Diabetologia 1974;10:607-610.
281. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science 1966;153:1127-1128.
282. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978;14:141-148.
283. Like AA, Chick WL. Studies in the diabetic mutant mouse, I: light microscopy and radioautography of pancreatic islets. Diabetologia 1970;6:207-215.
284. Chan TM, Dehaye JP. Hormone regulation of glucose metabolism in the genetically obese-diabetic mouse (db/db): glucose metabolism in the perfused hindquarters of lean and obese mice. Diabetes 1981;30:3211-3218.
285. Koranyi L, James D, Mueckler M, et al. Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice. . Clin Invest 1995;85:962-967.
286. Shargill NS, Tatoyan A, el-Refai MF, et al. Impaired insulin receptor phosphorylation in skeletal muscle membranes of db/db mice: the use of a novel skeletal muscle plasma membrane preparation to compare insulin binding and stimulation of receptor phosphorylation. Biochem Biophys Res Commun 1986;137:286-294.
287. Michaud EJ, Mynatt RL, Miltenberger RJ, et al. Role of the agouti gene in obesity. . Endocrinol 1997;155:207-209.
288. Miltenberger RJ, Mynatt RL, Wilkinson JE, et al. The role of the agouti gene in the yellow obese syndrome. . Nutr 1997;137:1902S-1907S.
289. Bultman S, Michaud E, Woychik R. Molecular characterization of the mouse agouti locus. Cell 1992;71:1195-1204.
290. Duhl DM, Stevens ME, Vrieling H, et al. Pleiotropic effects of the mouse lethal yellow (Ay) mutation explained by deletion of a maternally expressed gene and the simultaneous production of agouti fusion RNAs. Development 1994;120:1695-1708.
291. Michaud EJ, van Vugt MJ, Bultman SJ, et al. Differential expression of a new dominant agouti allele (Aiapy) is correlated with methylation state and is influenced by parental lineage. Genes Dev 1994;8:1463-1472.
292. Michaud EJ, Bultman SJ, Klebig ML, et al. A molecular model for the genetic and phenotypic characteristics of the mouse lethal yellow (Ay) mutation. Proc Natl Acad Sci U S A 1994;91:2562-2566.
293. Miller M, Duhl D, Vrieling H, Cordes S, et al. Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 1993;7:454-467.
294. Claycombe KJ, Wang Y, Jones BH, et al. Transcriptional regulation of the adipocyte fatty acid synthase gene by agouti: interaction with insulin. Physiol Genomics 2000;3:157-162.
295. Claycombe KJ, Xue BZ, Mynatt RL, et al. Regulation of leptin by agouti. Physiol Genomics 2000;2:101-105.
296. Jones BH, Kim JH, Zemel MB, et al. Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity. Am J Physiol 1996;270:E192-E196.
297. Zemel MB, Kim JH, Woychik RP, et al. Agouti regulation of intracellular calcium: role in the insulin resistance of viable yellow mice. Proc Natl Acad Sci U S A 1995;92:4733-4737.
298. Zemel MB. Insulin resistance vs. hyperinsulinemia in hypertension: insulin regulation of Ca2+ transport and Ca2+-regulation of insulin sensitivity. . Nutr 1995;125:1738S-1743S.
299. Sekiguchi F, Ishibashi K, Kawamoto Y, et al. Diabetic peculiarity of the ALSAy and ALR-Ay strains. Exp Anim 1991;40:323-329.
300. Frigeri LG, Wolff GL, Robel G. Impairment of glucose tolerance in yellow (Avy/A) (BALB/c X VY) F-1 hybrid mice by hyperglycemic peptide(s) from human pituitary glands. Endocrinology 1983;113:2097-2105.
301. Gill AM, Yen TT. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 1991;48:703-710.
302. Warbritton A, Gill AM, Yen TT, et al. Pancreatic islet cells in preobese yellow Avy/-mice: relation to adult hyperinsulinemia and obesity. Proc Soc Exp Biol Med 1994;206:145-151.
303. Salem MA, Lewis UJ, Haro LS, et al. Effects of hypophysectomy and the insulin-like and anti-insulin pituitary peptides on carbohydrate metabolism in yellow Avy/A (BALB/c x VY)F1 hybrid mice. Proc Soc Exp Biol Med 1989; 191:408-419.
304. Salem MA, Wolff GL. Potentiation of response to insulin and anti-insulin action by two human pituitary peptides in lean agouti A/a, obese yellow Avy/A, and C57BL/6J-ob/ob mice. Proc Soc Exp Biol Med 1989;191:113-123.
305. Shimizu H, Shargill NS, Bray GA. Adrenalectomy and response to corticosterone and MSH in the genetically obese yellow mouse. Am J Physiol 1989;256:R494-R500.
306. Shimizu H, Shargill NS, Bray GA, et al. Effects of MSH on food intake, body weight and coat color of the yellow obese mouse. Life Sci 1989;45:543-552.
307. Mathews CE, Bagley RB, Caldwell JC, et al. NIDDM in a new mouse model elicited by low free radical scavenging potential combined with behavioral and dietary stress. Diabetes 2001;50:A517.
308. Hasegawa G, Hata M, Nakano K, et al. Diabetic syndrome in the NON mouse. In: Sakamoto N, Hotta N, Uchida K, eds. Current concepts of a new animal model: the NON mouse. Amsterdam: Elsevier Science Publishers, 1992: 41-50.
309. Rebuffe-Scrive M, Surwit R, Feinglos M, et al. Regional fat distribution and metabolism in a new mouse model (C57BL/6J) of non-insulin-dependent diabetes mellitus. Metabolism 1993;42:1405-1409.
310. Wencel HE, Smothers C, Opara EC, et al. Impaired second phase insulin response of diabetes-prone C57BL/6J mouse islets. Physiol Behav 1995;57: 1215-1220.
311. Lee SK, Opara EC, Surwit RS, et al. Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 1995;11:206-211.
312. Surwit RS, Feinglos MN, Rodin J, et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 1995;44:645-651.
313. Surwit RS, Edwards CL, Murthy S, et al. Transient effects of long-term leptin supplementation in the prevention of diet-induced obesity in mice. Diabetes 2000;49:1203-1207.
314. Surwit R, Seldin M, Kuhn C, et al. Diet-induced obesity and diabetes in C57BL/6J and C57BL/KsJ mice. Mouse Genome 1994;92:523-525.
315. Livingston EG, Feinglos MN, Kuhn CM, et al. Hyperinsulinemia in the pregnant C57BL/6J mouse. Horm Metab Res 1994;26:307-308.
316. Parekh PI, Petro AE, Surwit RS, et al. Reversal of diet induced obesity and diabetes on C57BL/6J mice. Metabolism 1998;47:1089-1096.
317. Shibata M, Yasuda B. Spontaneously occurring diabetes in NSY mice. Jikken Dobutsu 1979;28:584-590.
318. Ueda H, Ikegami H, Kawaguchi Y, et al. Paternal-maternal effects on phenotypic characteristics in spontaneously diabetic Nagoya-Shibata-Yasuda mice. Metabolism 2000;49:561-656.
319. Ikegami H, Ueda H, Kawaguchi Y, et al. Positional cloning of susceptibility genes for non-insulin-dependent diabetes mellitus. Nippon Ronen Igakkai Zasshi 1998;35:290-293.
320. Ueda H, Ikegami H, Kawaguchi Y, et al. Genetic analysis of late-onset type 2 diabetes in a mouse model of human complex trait. Diabetes 1999;48: 1168-1174.
321. Shimizu K, Morita H, Niwa T, et al. Spontaneous amyloidosis in senile NSY mice. Acta Pathol Jpn 1993;43:215-221.
322. Shibata M, Kishi T, Yasuda B, et al. The inhibitory effect of lysozyme on the glomerular basement membrane thickening in spontaneous diabetic mice (NSY mice). Tohoku J Exp Med 1986;149:39-46.
323. Kim JH, Sen S, Avery CS, et al. Genetic analysis of a new mouse model for non-insulin dependent diabetes. Genomics 2001;74:273-286.
324. Suzuki W, Iizuka S, Tabuchi M, et al. A new mouse model of spontaneous diabetes derived from ddY strain. Exp Anim 1999;48:181-189.
325. Hirayama I, Yi Z, Izumi S, et al. Genetic analysis of obese diabetes in the TSOD mouse. Diabetes 1999;48:1183-1191.
326. Leiter EH, Reifsnyder PC, Flurkey K, et al. Non-insulin dependent diabetes genes in mice: deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes 1998;47:1287-1295.
327. Taylor BA, Phillips SJ. Obesity QTLs on mouse chromosomes 2 and 17. Genomics 1997;43:249-257.
328. Bielschowsky M, Bielschowsky F. A new strain of mice with hereditary obesity. Proc Univ Otago Med Sch 1953;31:29-31.
329. Crofford OB, Davis CK. Growth characteristics, glucose tolerance, and insulin sensitivity of New Zealand obese mice. Metabolism 1965;14:271-280.
330. Herberg L. Insulin resistance in abdominal and subcutaneous obesity: comparison of C57BL/6J-ob/ob with New Zealand obese mice. In: Shafrir E, Renold A, eds. Frontiers in diabetes research, II: lessons from animal diabetes. London: John Libbey, 1988:367-373.
331. Andrikopoulos S, Rosella G, Gaskin E, et al. Impaired regulation of hepatic fructose-1, 6-bisphosphatase in the New Zealand obese mouse model of NIDDM. Diabetes 1993;42:1731-1736.
332. Andrikopoulos S, Proietto J. The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1995;38:1389-1396.
333. Andrikopoulos S, Rosella G, Kaczmarczyk SJ, et al. Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse: an acquired defect. Metabolism 1996;45:622-626.
334. Proietto J, Larkins RG. A perspective on the New Zealand obese mouse. In: Shafrir E, ed. Lessons from animal models of diabetes, IV. London: Smith-Gordon, 1993:65-73.
335. Thorburn AW, Holdsworth A, Proietto J, et al. Differential and genetically separable associations of leptin with obesity-related traits. Int J Obes 2000; 24:742-750.
336. Reifsnyder PC, Churchill G, Leiter EH. Maternal environment and genotype interact to establish diabesity in mice. Genome Res 2000;10:1568-1578.
337. Plum L, Kluge R, Giesen K, et al. Type 2 diabetes-like hyperglycemia in a backcross model of NZO and SJL mice: characterization of a susceptibility locus on chromosome 4 and its relation with obesity. Diabetes 2000;49:1590-1596.
338. Veroni M, Proietto J, Larkins R. Evolution of insulin resistance in New Zealand obese mice. Diabetes 1991;40:1480-1487.
339. Larkins R, Simeonova L, Veroni M. Glucose utilization in relation to insulin secretion in NZO and C57BL mouse islets. Endocrinology 1980;107:1634-1638.
340. Gates RJ, Lazarus NR. The ability of pancreatic polypeptides (APP and BPP) to return to normal the hyperglycemia, hyperinsulinaemia, and weight gain of New Zealand obese mice. Horm Res 1977;8:189-202.
341. Gates RJ, Smith R, Hunt MI, et al. Return to normal of blood-glucose, plasma-insulin, and weight gain in New Zealand obese mice after implantation of islets of Langerhans. Lancet 1972;7777:567-570.
342. Gates R, Hunt M, Lazarus N. Further studies on the amelioration of the characteristics of New Zealand Obese (NZO) mice following implantation of islets of Langerhans. Diabetologia 1974;10:401-406.
343. Taylor BA, Wnek C, Schroeder D, et al. Multiple obesity QTLs identified in an intercross between the NZO (New Zealand obese) and the SM (small) mouse strains. Mamm Genome 2001;12:95-103.
344. Kluge R, Giesen K, Bahrenberg G, et al. Quantitative trait loci for obesity and insulin resistance (Nob1, Nob2) and their interaction with the leptin receptor allele (LeprA720T/T1044I) in New Zealand obese mice. Diabetologia 2000;43: 1565-1572.
345. Igel M, Becker W, Herberg L, et al. Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology 1997;138:4234-4239.
346. Melez KA, Harrison LC, Gilliam JN, et al. Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes 1980;29:835-840.
347. Melez KA, Attallah AM, Harrison ET, et al. Immune abnormalities in the diabetic New Zealand obese (NZO) mouse: insulin treatment partially suppresses splenic hyperactivity measured by flow cytometric analysis. Clin Immunol Immunopathol 1985;36:110-119.
348. Harrison LC, Itin A. A possible mechanism for insulin resistance and hyperglycaemia in New Zealand obese mice. Nature 1979;279:334-336.
349. Hamano Y, Hirose S, Ida A, et al. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. Blood 1998;92: 3772-3779.
350. Collins S, Daniel KW, Petro AE, et al. Strain-specific response to beta(3)-adrenergic receptor agonist treatment of diet-induced obesity in mice. Endocrinology 1997;138:405-413.
351. Berdanier CD. Non-insulin-dependent diabetes in the nonobese BHE/cdb rat. In: Shafrir E, ed. Lessons from animal diabetes. London: Smith-Gordon, 1994:231-246.
352. Mathews C, Everts H, Flatt W, et al. ATP production is reduced in rats having an ATPase 6 mutation. Int J Diabetes 2002 (in press).
353. Mathews CE, McGraw RA, Dean R, et al. Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats. Diabetologia 1999;42:35-40.
354. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996;45: 223-241.
355. Lakshmanan MR, Berdanier CD, Veech RL. Comparative studies on lipogenesis and cholesterogenesis in lipemic BHE rats and normal Wistar rats. Arch Biochem Biophys 1977;183:355-360.
356. Berdanier CD. Rat strain differences in gluconeogenesis by isolated hepatocytes. Proc Soc Exp Biol Med 1982;169:74-79.
357. Berdanier CD, Thomson AR. Comparative studies on mitochondrial respiration in four strains of rats rattus norvegicus. Comp Biochem Physiol 1986;85B: 531-535.
358. Deaver OE, Wander RC, McCusker RH, et al. Diet effects on membrane phospholipid fatty acids and mitochondrial function in BHE rats. . Nutr 1986; 116:1148-1155.
359. Kim MC, Berdanier CD. Glucose homeostasis in thyroxine-treated BHE/cdb rats fed corn oil or hydrogenated coconut oil. . Nutr Biochem 1993;4:10-19.
360. Hood DA, Simoneau J-A, Kelly AM, et al. Effect of thyroid status on the expression of metabolic enzymes during chronic stimulation. Am J Physiol 1992;263:C788-C793.
361. Soboll S. Thyroid hormone action on mitochondrial energy transfer. Biochim Biophys Acta 1993;1144:1-16.
362. Van Itallie CM. Thyroid hormone and dexamethasone increase the levels of a messenger ribonucleic acid for a mitochondrially encoded subunit but not for a nuclear-encoded subunit of cytochrome c oxidase. Endocrinology 1990;127:55-62.
363. Jarrett RJ, Keen H. Diurnal variation of oral glucose tolerance: a possible pointer to the evolution of diabetes mellitus. BMJ 1969;2:341-344.
364. Jarrett RJ, Keen H. Further observations on the diurnal variation of oral glucose tolerance. BMJ 1970;4:334-337.
365. Sassone-Corsi P. Molecular clocks: mastering time by gene regulation. Nature 1998;392:871-874.
366. Mathews CE, Wickwire K, Flatt W, et al. Attenuation of circadian rhythms of food intake and respiration in aging diabetes-prone BHE/Cdb rats. Am J Physiol 2000;279:R230-R238.
367. Mathews CE, McGraw R, Berdanier C. Apoint mutation in the mitochondrial DNA of diabetes-prone BHE/cdb rats. FASEB J 1995;9:1638-1642.
368. Gadaleta G, Pepe G, DeCandia G, et al. The complete nucleotide sequence of the Rattus norvegicus mitochondrial genome: cryptic signals revealed by comparative analysis between vertebrates. . Mol Evol 1989;28:497-516.
369. Brown GC, Lakin-Thomas PL, et al. Control of respiration and oxidative phosphorylation in isolated rat liver cells. Eur J Biochem 1990;192:355-362.
370. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992;284:1-13.
371. Hafner RP, Brown GC, Brand MD. Analysis of the control of respiration rate, phosphorylation rate, proton leak rate and protonmotive force in isolated mitochondria using the 'top-down' approach of metabolic control theory. Eur J Biochem 1990;188:313-319.
372. Kim S-B, Berdanier CD. Oligomycin sensitivity of mitochondrial F1Fo ATPase in diabetes prone BHE/cdb rats. Am J Physiol 1999;277:E702-E707.
373. Tarres MC, Martinez SM, Liborio MM, et al. Diabetes mellitus en una linea endocriada de ratas. Mendeliana 1981;5:39-48.
374. Tarres MC, Martinez SM, Montenegro SM, et al. Influence of gonadectomy in eSS diabetic rats. Rev Esp Fisiol 1997;53:211-216.
375. Tarres MC, Martinez SM, Montenegro SM, et al. Relationship of diet, biomass and expression of diabetes in eSS rats. Medicina (B Aires) 1990;50:235-243.
376. Martinez SM, Tarres MC, Montenegro S, et al. Intermittent dietary restriction in eSS diabetic rats. Effects on metabolic control and skin morphology. Acta Diabetol Lat 1990;27:329-336.
377. Martinez SM, Tarres MC, Montenegro S, et al. Spontaneous diabetes in eSS rats. Acta Diabetol Lat 1988;25:303-313.
378. Gomez Dumm CL, Semino MC, Gagliardino JJ. Quantitative morphological changes in endocrine pancreas of rats with spontaneous diabetes mellitus. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57:375-381.
379. Gomez Dumm CL, Semino MC, Gagliardino JJ. Sequential morphological changes in pancreatic islets of spontaneously diabetic rats. Pancreas 1990;5: 533-539.
380. de Gomez Dumm IN, Montenegro S, Tarres MC, et al. Early lipid alterations in spontaneously diabetic rats. Acta Physiol Pharmacol Ther Latinoam 1998;48: 228-234.
381. Daniele SM, Arriaga S, Martinez SM, et al. Onset and evolution of nephropathy in rats with spontaneous diabetes mellitus. . Physiol Biochem 2000;56:45-53.
382. Goto Y, Kakizaki M, Masaki N. Spontaneous diabetes produced by selective breeding of normal wistar rats. Proc Jpn Acad 1975;51:80-85.
383. Suzuki K-I, Goto Y, Toyata T. Spontaneously diabetic GK (Goto-Kakizaki) rats. In: Shafrir E, ed. Lessons from animal diabetes. London: Smith-Gordon, 1992:107-116.
384. Portha B, Serradas P, Bailbe D, et al. D-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 1991;40:486-491.
385. Movassat J, Saulnier C, Serradas P, et al. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 1997;40:916-925.
386. Movassat J, Saulnier C, Portha B. Beta-cell mass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent diabetes mellitus. Diabete Metab 1995;21:365-370.
387. Portha B, Giroix MH, Serradas P, et al. Beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. Diabetes 2001;50:S89-S93.
388. Salehi A, Henningsson R, Mosen H, et al. Dysfunction of the islet lysosomal system conveys impairment of glucose-induced insulin release in the diabetic GK rat. Endocrinology 1999;140:3045-3053.
389. Ostenson CG, Abdel-Halim SM, Rasschaert J, et al. Deficient activity of FADlinked glycerophosphate dehydrogenase in islets of GK rats. Diabetologia 1993;36:722-726.
390. Ostenson CG, Khan A, Abdel-Halim SM, et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993;36:3-8.
391. Tsuura Y, Ishida H, Okamoto Y, et al. Glucose sensitivity of ATP-sensitive K+ channels is impaired in beta-cells of the GK rat: a new genetic model of NIDDM. Diabetes 1993;42:1446-1453.
392. Tsuura Y, Ishida H, Okamoto Y, et al. Reduced sensitivity of dihydroxyacetone on ATP-sensitive K+ channels of pancreatic beta cells in GK rats. Diabetologia 1994;37:1082-1087.
393. Nagamatsu S, Nakamichi Y, Yamamura C, et al. Decreased expression of t-SNARE, syntaxin 1, and SNAP-25 in pancreatic beta-cells is involved in impaired insulin secretion from diabetic GK rat islets: restoration of decreased t-SNARE proteins improves impaired insulin secretion. Diabetes 1999;48:2367-2373.
394. Abdel-Halim S, Guenifi A, Luthman H, et al. Impact of diabetic inheritance on glucose tolerance and insulin secretion in spontaneously diabetic GK-Wistar rats. Diabetes 1994;43:281-288.
395. Galli J, Li L-S, Glaser A, Östenson C-G, et al. Genetic analysis of non-insulin dependent diabetes mellitus in the GK rat. Nat Genet 1996;12:31-37.
396. Galli J, Fakhrai-Rad H, Kamel A, et al. Pathophysiological and genetic characterization of the major diabetes locus in GK rats. Diabetes 1999;48: 2463-2470.
397. Fakhrai-Rad H, Nikoshkov A, Kamel A, et al. Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet 2000;9:2149-2158.
398. Kawano K, Hirashima T, Saitoh Y, et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otkuka Long-Evans Tokushima fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
399. Kawano K, T. H, Mori S, Natori T. OLEFT (Otsuka Long-Evans Tokushima fatty) rat: a new NIDDM rat strain. Diabet Res Clin Pract 1994;24:S317-S320.
400. Shi K, Mizuno A, Sano T, et al. Sexual difference in the incidence of diabetes mellitus in Otsuka-Long-Evans-Tokushima-fatty rats: effects of castration and sex hormone replacement on its incidence. Metabolism 1994;43: 1214-1220.
401. Kawano K, Hirashima T, Mori S, et al. Spontaneously diabetic rat "OLETF" as a model for NIDDM in humans. In: Shafrir E, ed. Lessons in animal diabetes. Boston: Birkhauser, 1996:225-236.
402. Toide K, Man ZW, Asahi Y, et al. Glucose transporter levels in a male spontaneous non-insulin-dependent diabetes mellitus rat of the Otsuka Long-Evans Tokushima Fatty strain. Diabetes Res Clin Pract 1997;38:151-160.
403. Sato T, Man ZW, Toide K, et al. Plasma membrane content of insulin-regulated glucose transporter in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a model of non-insulin-dependent diabetes mellitus. FEBS Lett 1997;407:329-332.
404. Ishida K, Mizuno A, Murakami T, et al. Obesity is necessary but not sufficient for the development of diabetes mellitus. Metabolism 1996;45:1288-1295.
405. Okauchi N, Mizuno A, Zhu M, et al. Effects of obesity and inheritance on the development of non-insulin-dependent diabetes mellitus in Otsuka-Long-Evans-Tokushima fatty rats. Diabet Res Clin Pract 1995;29:1-10.
406. Hirashima T, Kawano K, Mori S, et al. A diabetogenic gene (Odb-1) assigned to the X-chromosome in Oletf rats. Diabet Res Clin Pract 1995;27:91-96.
407. Nara V, Gao M, Sawamura M, et al. Genetic-analysis of non-insulin-dependent diabetes-mellitus in the Otsuka Long-Evans Tokushima fatty rat. Biochem Biophys Res Commun 1997;241:200-204.
408. Kanemoto N, Hishigaki H, Miyakita A, et al. Genetic dissection of "OLETF," a rat model for non-insulin-dependent diabetes mellitus. Mamm Genome 1998;9:419-425.
409. Hirashima T, Kawano K, Mori S, et al. Adiabetogenic gene, ODB2, identified on chromosome 14 of the OLETF rat and its synergistic action with ODB1. Biochem Biophys Res Commun 1996;224:420-425.
410. Moralejo DH, Ogino T, Wei SW, et al. A major quantitative trait locus colocalizing with cholecystokinin type a receptor gene influences poor pancreatic proliferation in a spontaneously diabetogenic rat. Mamm Genome 1998;9: 794-798.
411. Takiguch S, Takata Y, Kataoka K, et al. Disrupted cholecystokinin type-a receptor (CCKAR) gene in OLETF rats. Gene 1997;197:169-175.
412. Takiguchi S, Takata Y, Takahash N, et al. A disrupted cholecystokinin-A receptor gene induces diabetes in obese rats synergistically with Odb1 gene. Am J Physiol 1998;37:E265-E270.
413. Kawano K, Mori S, Hirashima T, et al. Examination of the pathogenesis of diabetic nephropathy in OLETF rats. . Vet Med Sci 1999;61:1219-1228.
414. Barrie HJ, Askanazy CL, Smith GW. More glomerular changes in diabetes. Can Med Assoc J 1952;66:428-435.
415. Kosegawa I, Katayama S, Kikuchi C, et al. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens Res 1996;19:37-41.
416. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000;101:899-907.
417. Mizushige K, Noma T, Yao L, et al. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima fatty rats. . Cardiovasc Pharmacol 2000;35:150-155.
418. Yao L, Mizushige K, Noma T, et al. Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment. Angiology 2001;52:53-57.
419. Okauchi N, Mizuno A, Yoshimoto S, et al. Is caloric restriction effective in preventing diabetes mellitus in the Otsuka Long Evans Tokushima fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus? Diabetes Res Clin Pract 1995;27:97-106.
420. Shima K, Shi K, Sano T, et al. Is exercise training effective in preventing diabetes mellitus in the Otsuka-Long-Evans-Tokushima fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus? Metabolism 1993;42: 971-977.
421. Shima K, Shi K, Mizuno A, et al. Effects of difference in amount of exercise training on prevention of diabetes mellitus in the Otsuka-Long-Evans-Tokushima fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994;23:147-154.
422. Shima K, Shi K, Mizuno A, et al. Exercise training has a long-lasting effect on prevention of non-insulin-dependent diabetes mellitus in Otsuka-Long-Evans-Tokushima fatty rats. Metabolism 1996;45:475-480.
423. Jia DM, Tabaru A, Akiyama T, et al. Troglitazone prevents fatty changes of the liver in obese diabetic rats. . Gastroenterol Hepatol 2000;15:1183-1191.
424. Kosegawa I, Chen S, Awata T, et al. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima fatty rats. Clin Exp Hypertens 1999;21:199-211.
425. Zucker LM, Zucker TF. Fatty, a new mutation in the rat. . Hered 1961;52: 275-278.
426. Peterson RG, Shaw WN, Neel M-A, et al. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News 1990;32:16-19.
427. Cockburn BN, Ostrega DM, Sturis J, et al. Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes. Diabetes 1997;46:1434-1439.
428. Tokuyama Y, Sturis J, Depaoli AM, et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 1995;44:1447-1457.
429. Zhou YP, Cockburn BN, Pugh W, et al. Basal insulin hypersecretion in insulin-resistant Zucker diabetic and Zucker fatty rats: role of enhanced fuel metabolism. Metabolism 1999;48:857-864.
430. Zawalich WS, Kelley GG. The pathogenesis of NIDDM: the role of the pancreatic beta cell. Diabetologia 1995;38:986-991.
431. Sturis J, Pugh WL, Tang J, et al. Alterations in pulsatile insulin secretion in the Zucker diabetic fatty rat. Am J Physiol 1994;267:E250-E259.
432. Sturis J, Pugh WL, Tang J, et al. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am J Physiol 1995;269: E786-E792.
433. Orci L, Ravazzola M, Baetens D, et al. Evidence that down-regulation of betacell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci U S A 1990;87:9953-9957.
434. MacDonald MJ, Tang J, Polonsky KS. Low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of Zucker diabetic fatty rats. Diabetes 1996;45:1626-1630.
435. Slieker LJ, Sundell KL, Heath WF, et al. Glucose transporter levels in tissues of spontaneously diabetic Zucker fa/fa rat (ZDF/drt) and viable yellow mouse (Avy/a). Diabetes 1992;41(2):187-193.
436. Lee Y, Hirose H, Zhou YT, et al. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes 1997;46:408-413.
437. Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 1994;91:10878-10882.
438. Zhou YT, Shimabukuro M, Lee Y, et al. Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: role in the pathogenesis of lipotoxic diabetes. Diabetes 1998;47:1904-1908.
439. Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesityinduced beta cell disease. . Clin Invest 1997;100:290-295.
440. Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998;95: 2498-2502.
441. Shimabukuro M, Higa M, Zhou YT, et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. . Biol Chem 1998;273:32487-32490.
442. Roe MW, Worley JF, Tokuyama Y, et al. NIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activity. Am J Physiol 1996;270: E133-E140.
443. Chua SCJ, Chung W, Wu-Peng X, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271:994-996.
444. Truett G, Bahary N, Friedman J, et al. Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db). Proc Natl Acad Sci U S A 1991;88:7806-7809.
445. Chua SC Jr, White DW, Wu-Peng XS, et al. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 1996;45:1141-1143.
446. Phillips M, Liu Q, Hammond H, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996;13:18-19.
447. White D, Wang Y, Chua S, et al. Constitutive and impaired signaling of leptin receptors containing the Gln→Pro extracellular domain fatty mutation. Proc Natl Acad Sci U S A 1997;94:10657-10662.
448. Griffen SC, Wang J, German MS. Agenetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes 2001;50: 63-68.
449. Harmon JS, Gleason CE, Tanaka Y, et al. In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 1999;48:1995-2000.
450. Ohneda M, Inman LR, Unger RH. Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia 1995;38:173-179.
451. Sreenan S, Keck S, Fuller T, et al. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 1999;276:E1119-E1129.
452. Zhang B, Graziano MP, Doebber TW, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in zucker diabetic fatty rats and db/db mice. . Biol Chem 1996;271:9455-9459.
453. Shimabukuro M, Zhou YT, Lee Y, et al. Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. Biochem Biophys Res Commun 1997;237:359-361.
454. Brown KK, Henke BR, Blanchard SG, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999;48:1415-1424.
455. Smith SA, Lister CA, Toseland CD, et al. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000;2:363-372.
456. Shibata T, Takeuchi S, Yokota S, et al. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000;130:495-504.
457. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 1998;244:678-682.
458. Shimoshige Y, Ikuma K, Yamamoto T, et al. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats. Metabolism 2000;49:1395-1399.
459. Tofovic SP, Kusaka H, Kost CK, et al. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail 2000;22:387-406.
460. Aharonson Z, Shani J, Sulman FG. Hypoglycaemic effect of the salt bush (Atriplex halimus)-a feeding source of the sand rat (Psammomys obesus). Diabetologia 1969;5:379-383.
461. Ziv E, Shafrir E. Psammomys obesus: nutritionally induced NIDDM-like syndrome on a "thrifty gene" background. In: Shafrir E, ed. Lessons from animal diabetes. London: Smith-Gordon, 1995:285-300.
462. Borenshtein D, Ofri R, Werman M, et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev 2001;17:44-50.
463. Shafrir E, Spielman S, Nachliel I, et al. Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diabetes Metab Res Rev 2001;17:55-66.
464. Hahn HJ, Gottschling HD, Schafer H. Apparent discrepancy between the insulin secretory responses in vivo and in vitro in carbohydrate-intolerant sand rats. Diabetologia 1979;17:367-369.
465. Kanety H, Moshe S, Shafrir E, et al. Hyperinsulinemia induces a reversible impairment in insulin receptor function leading to diabetes in the sand rat model of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1994;91:1853-1857.
466. Ikeda Y, Olsen GS, Ziv E, et al. Cellular mechanism of nutritionally induced insulin resistance in Psammomys obesus: overexpression of protein kinase epsilon in skeletal muscle precedes the onset of hyperinsulinemia and hyperglycemia. Diabetes 2001;50:584-592.